drugset / Trial / NCT01615614

A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants

NCT01615614

Phase 1 Completed 20 enrolled Janssen R&D Ireland
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the pharmacokinetics of different dosing regimens of rilpivirine in combination with rifabutin in healthy participants.

Timeline

Start
2012-04
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifabutin Small molecule 150 mg Oral
Subject Rilpivirine Small molecule 25 mg Oral
Subject Rilpivirine Small molecule 50 mg Oral

Indications

No indication recorded.